Eli Lilly has already published preliminary data that shows his medicine for obesity, Zepbound surpassed Novo Nordisk’s Wogovy about weight loss measures in a face -to -face clinical trial. The most detailed results, including the key secondary measures of the phase 3 study, provide a greater vision of the comparison, including a key measure that analysts say it helps to give the product Lilly a competitive advantage.
In preliminary results, Zepbound treatment for 72 weeks led patients to lose an average of 20.2% of body weight versus 13.7% for those in Wogovy’s arm, fulfilling the main objective of the phase 3B study, Lilly reported data on data on data on data on data data data data data data data 44. At the European Congress meeting on obesity on obesity and published simultaneously in the New England Journal of Medicine.
To the extent of how many patients they achieved at least 10% weight loss, Lilly said that 81.6% or participants treated with Zepbound achieved this secondary end point compared to 40.1% of the treaties with Wegovy. Lilly’s drug beat Wagovy in three additional weight reduction goals in the study, called Surmount-5. In a fifth secondary end point of the measurement change in the circumference of the waist, the Zepbound Group achieved a higher reduction of 18.4 cm (approximately 7.2 inches) compared to the 13 cm anverage (approximately 5.1 inches) for the WOGOVY arm.
“In the Surmount-5 essay, Zepbound demonstrated a significant magnitude of weight reduction compared to tires in all comparisons,” said Leonard Glass, senior vice president of global medical matters, Lilly, in a prepared statement. “These data confirm Zepbound as a leading treatment option for people who live with obesity and equip medical care providers with critical ideas to make well -informed treatment decisions as part of a comprehensive obesity care plan.”
The main pharmaceutical ingredient in Zepbound is the tirzepatido, a peptide designed to join and activate the GLP-1 and GIP receptors to provoke feelings of Sattyy. On the contrary, the semaglutida, the main ingredient in Wogovy, only activates the GLP-1 receiver. The gastrointestinal side effects are common throughout the kind of these metabolic medications.
Lilly said that gastrointestinal complications reported for her drug in the head to head study as of mild to moderate gravity, although 6.1% of those of the zero arm discontinued the treatment due to adure events. In comparison, 8.0% of the participants, Wogovy’s arm, discontinued the treatment. Lilly Company added that the study was not driven to compare security and toluality between the two medications.
Tolerability was one of the key comparison measures absent from the release of preliminary data from Lilly at the end of last year. For Readink Partners analyst David Risinger, the now published details about this measure are welcome news for Lilly. Nausea, constipation, Darrhea and vomiting rates were similar for both drugs. Zepbound’s demonstration of greater weight loss with tolerability comparable to Wegovy confirms the superior benefit-risgo relationship of Lilly’s drug, Risinger wrote in a note to investors on Monday.
The study of Surmount-5 face to face enrolled 751 participants with obesity, as well as the hypertension of comorbidities, dyslipidemia, obstructive sleep apnea or cardiovascular disease. These participants had no diabetes. Those who completed this clinical trial continue in an extension study that could support the use of the experimental oral drug of Lilly, orforglipron, as an oral maintenance treatment.
The participants who continue in the extension study were randomly assigned to receive the experimental LPG-1 oral medication once a day of Lilly, Orforglipron or a placebo. The main objective of this 52 -week study is to evaluate the capacity of orforgripron to maintain the reduction of body weight achieved after initial treatment with zero injectable once in the week. This study is expected to evaluate about 300 patients, it will be completed in January 2026.
Orforglipron is an oral molecule designed to activate the GLP-1 receiver. Last month, Lilly reported preliminary phase 3 results for orforglipron that shows statistically significant reductions in blood sugar measures and body weight in patients with type 2 diabetes. According to these results, Lilly said it is a preparation to present regulatory presentations for the medication both in weight control and in type 2 diabetes.
Photo by Eli Lilly